Answers are grounded in this paper and cite their sources.
purpose : to assess the macular and choroidal alterations using optical coherence tomography imaging at baseline and one month after receiving intravitreal antivascular growth factor (anti-VEGF) (ranibizumab) therapy in patients who had diabetic macular edema .Methods: This was a prospective clinical study which was conducted on twenty eyes with type 2 diabetes with clinically significant macular edema . The intravitreal injection (IVI) of ranibizumab 0.3 mg was administered to the patients (0.05 mL). Prior to the injection and one month later, the central macular thickness, subfoveal choroidal thickness , choroidal thickness 500 m temporal and nasal to fovea were all assessed by SD-OCT. Results: Postoperatively, the mean nasal, subfoveal and temporal choroidal thickness were 175.7±34.55, 185.6±29.13 and 183.9±34.62µm respectively. There was a statistically significant change in the best corrected visual acuity BCVA (p =0.04), the mean preoperative BCVA was 0.875±0.202 while the mean postoperative BCVA was 0.76 ± 0.22. The postoperative BCVA had a statistically significant (p= 0.03) negative correlation with the retinal thickness (r= -0.242), while it didn’t have a significant correlation with the nasal, subfoveal and temporal choroidal thickness (p= 0.275, 0.248 and 0.343) respectively. Conclusion: Injection of LUCENTIS® resulted in a decrease in choroidal thickness, which is a reflection of the impact LUCENTIS® had on the choroidal vasculature. There was a substantial difference between the BCVA before injection and the BCVA one month after it, and this difference had a clear link to the thickness of the retina but not the thickness of the choroids.
No takes yet. Share an insight, caveat, or question.
Mahmoud et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: